A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma Academic Article uri icon


MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Brain Neoplasms
  • Glioma


  • The purpose of this study was to evaluate the activity of single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients with recurrent anaplastic glioma were treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations were repeated every 4 weeks. Correlative dynamic contrast-enhanced MR and (18)fluorodeoxyglucose PET imaging studies were obtained to evaluate physiologic changes in tumor and tumor vasculature at time points including baseline, 96 h after the first dose, and after the first 4 weeks of therapy. Median overall survival was 12 months (95% confidence interval [CI]: 6.08-22.8). Median progression-free survival was 2.93 months (95% CI: 2.01-4.93), and 6-month progression-free survival was 20.9% (95% CI: 10.3%-42.5%). Thirteen (43%) patients achieved a partial response. The most common grade ≥ 3 treatment-related toxicities were hypertension, hypophosphatemia, and thromboembolism. Single-agent bevacizumab produces significant radiographic response in patients with recurrent anaplastic glioma but did not meet the 6-month progression-free survival endpoint. Early change in enhancing tumor volume at 4 days after start of therapy was the most significant prognostic factor for overall and progression-free survival.

publication date

  • October 2011



  • Academic Article



  • eng

PubMed Central ID

  • PMC3177658

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nor091

PubMed ID

  • 21865400

Additional Document Info

start page

  • 1143

end page

  • 50


  • 13


  • 10